NHLBI Information & Resources on COVID-19北斗棋牌客服电话 充值
During this rapidly evolving situation and time of great uncertainty, the NHLBI shares concerns about the pandemic. We are working hard to support necessary research that will answer key questions aimed at keeping people healthy. For additional information on NHLBI’s efforts, read the 博客 from Gary H. Gibbons, M.D., director of NHLBI. Bookmark this page and return to it for updates on NHLBI COVID-19 activities. For questions and ideas regarding NHLBI’s COVID-19 related activities, email us at nhlbi资讯@nhlbi.nih.gov.
A clinical trial to evaluate the safety and effectiveness of hydroxychloroquine for the treatment of adults hospitalized with coronavirus disease 2019 (COVID-19) has been stopped by the National Institutes of Health. A data and safety monitoring board (DSMB) met late Friday and determined that while there was no harm, the study drug was very unlikely to be beneficial to hospitalized patients with COVID-19.
NHLBI-funded researchers tackle big questions with large study of patients hospitalized with COVID-19. The doctors on the front lines of the coronavirus pandemic may be aware of the health impacts that face survivors of mass shootings or natural disasters, but the highly contagious virus—one of the deadliest in history—is forcing them to grapple with a new question: if people who have beaten the disease should worry about their long-term health.
This year, we recognize that the coronavirus disease 2019 (COVID-19) pandemic is creating concern and uncertainty for many people around the globe, including those with asthma. The disease can affect the nose, throat, and lungs, cause an asthma attack, and possibly lead to pneumonia and acute respiratory disease.
Roughly two-thirds of patients given antiviral remdesivir on a compassionate use basis to treat COVID-19 showed clinical improvement, according to preliminary results from a Gilead trial published in the New England Journal of Medicine. The study is co-authored by Rear Admiral Richard Childs, M.D., assistant surgeon general and lung specialist at NHLBI, who led a team sent to Japan to screen Americans aboard the Diamond Princess cruise ship and bring them home.
Study is enrolling hospitalized patients with COVID 19
A clinical trial to evaluate the safety and effectiveness of hydroxychloroquine for the treatment of adults hospitalized with coronavirus disease 2019 (COVID-19) has begun, with the first participants now enrolled in Tennessee.
An experimental antiviral drug called remdesivir appeared to be beneficial when tested on a small group of American cruise ship passengers treated for the coronavirus (COVID-19) in Japan. Read more about the ongoing work by Rear Admiral Richard Childs, M.D., assistant U.S. surgeon general and clinical director at NHLBI.
Last Updated May 15, 2020